HUTCHMED (HCM) News Today → Trump Asset Seizure Threat Alert: Could Your Savings Be Next? (From American Hartford Gold Group) (Ad) Free HCM Stock Alerts $20.85 +1.38 (+7.09%) (As of 09:32 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committeeglobenewswire.com - May 8 at 4:30 AMHUTCHMED (NASDAQ:HCM) Shares Gap Up to $19.15marketbeat.com - May 6 at 5:54 PMHUTCHMED (NASDAQ:HCM) Shares Gap Up to $18.16marketbeat.com - April 29 at 12:12 PMHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takedaglobenewswire.com - April 26 at 8:30 AMHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volumemarketbeat.com - April 17 at 1:11 PMHUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.66marketbeat.com - April 16 at 12:44 PMHUTCHMED (NASDAQ:HCM) Stock Price Down 4%marketbeat.com - April 5 at 2:59 PMHUTCHMED Highlights Data to be Presented at AACR Congress 2024finance.yahoo.com - April 5 at 9:18 AMHUTCHMED (China) Limited (NASDAQ:HCM) Forecasted to Post FY2025 Earnings of $0.05 Per Sharemarketbeat.com - April 5 at 9:09 AMHUTCHMED Highlights Data to be Presented at AACR Congress 2024globenewswire.com - April 5 at 4:30 AMHUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPAmarkets.businessinsider.com - April 2 at 2:12 AMHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Statusglobenewswire.com - April 2 at 12:30 AMDo Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?finance.yahoo.com - March 28 at 7:10 AMHUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCglobenewswire.com - March 27 at 8:00 PMHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in Chinaglobenewswire.com - March 21 at 8:00 PMHUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.34marketbeat.com - March 21 at 3:51 PMHutchmed Is Turning Profitableseekingalpha.com - March 20 at 8:55 AMHUTCHMED (NASDAQ:HCM) Stock Price Up 5.5%marketbeat.com - March 15 at 12:37 PMAffimed N.V., Hutchmed, Annexon among healthcare moversmsn.com - March 14 at 10:33 AMHUTCHMED (NASDAQ:HCM) Raised to Buy at StockNews.commarketbeat.com - March 11 at 11:15 PMHUTCHMED (China) Limited (NASDAQ:HCM) Stake Cut by Schroder Investment Management Groupmarketbeat.com - March 7 at 8:59 AMHUTCHMED (NASDAQ:HCM) Shares Gap Down to $15.12marketbeat.com - March 5 at 1:23 PMHUTCHMED (China) Limited (HCM) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 12:16 PMHUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)finance.yahoo.com - March 1 at 2:14 AMHUTCHMED Reports 2023 Full Year Results and Provides Business Updatesglobenewswire.com - February 28 at 6:30 AMHUTCHMED (HCM) to Release Quarterly Earnings on Wednesdaymarketbeat.com - February 27 at 2:26 AMAcadian Asset Management LLC Makes New Investment in HUTCHMED (China) Limited (NASDAQ:HCM)marketbeat.com - February 25 at 6:23 AMHCM Mar 2024 17.500 callfinance.yahoo.com - February 17 at 10:11 AMHUTCHMED (NASDAQ:HCM) Shares Gap Down to $14.01marketbeat.com - February 14 at 12:01 PMHUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Sessionfinance.yahoo.com - February 6 at 9:18 PMHUTCHMED (NASDAQ:HCM) Shares Gap Up to $12.08marketbeat.com - February 6 at 11:39 AMHUTCHMED (China) Limited: HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnershipfinanznachrichten.de - February 2 at 9:46 AMInmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMEDfinance.yahoo.com - February 2 at 9:46 AMHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancerfinance.yahoo.com - January 30 at 12:47 AMHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volumemarketbeat.com - January 29 at 1:35 PMHUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Decrease in Short Interestmarketbeat.com - January 17 at 12:44 AMChinese regulators accept HUTCHMED application for solveplenibmsn.com - January 11 at 1:15 PMHUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Statusfinance.yahoo.com - January 10 at 8:03 PMHUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Updatemarketbeat.com - January 3 at 9:19 PMHUTCHMED (China) Limited (0013.HK)ca.finance.yahoo.com - December 24 at 1:30 PMHUTCHMED (China) Limited Forecasted to Earn FY2023 Earnings of $0.23 Per Share (NASDAQ:HCM)marketbeat.com - December 21 at 7:46 AMHUTCHMED (NASDAQ:HCM) Stock Rating Reaffirmed by Cantor Fitzgeraldmarketbeat.com - December 21 at 7:36 AMHUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Termsfinance.yahoo.com - December 13 at 3:26 AMHUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in Chinafinance.yahoo.com - December 12 at 9:56 PMUniSuper Management Pty Ltd Invests $6.84 Million in HUTCHMED (China) Limited (NASDAQ:HCM)marketbeat.com - December 8 at 7:41 AMHUTCHMED (China) Limited: HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congressesfinanznachrichten.de - December 1 at 10:12 PMHUTCHMED Deserves An Upgrade After U.S. FDA Approval Of Cancer Drugseekingalpha.com - December 1 at 12:11 PMGoldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Knowmarkets.businessinsider.com - November 10 at 12:51 PMHUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancerfinance.yahoo.com - November 8 at 10:45 PMHutchmed: Progressing, But We Would Like More Clarity On Profit Marginsseekingalpha.com - October 19 at 6:23 PM Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (Ad)Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW. GET THE FREE GUIDE HCM Media Mentions By Week HCM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼0.530.36▲Average Medical News Sentiment HCM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼21▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PBH News RARE News XENE News IDYA News JANX News AXSM News ARWR News BHVN News FOLD News SMMT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryObama’s Forever Term [exposed]Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
